GnRH antagonist, cetrorelix, for pituitary suppression in modern, patient-friendly assisted reproductive technology

Bibliography

• Boivin J, Bunting L, Collins JA, Nygren KG. International estimates of infertility prevalence and treatment-seeking: potential need and demand for infertility medical care. Hum Reprod 2007;22:1506-12
   PubMed Web of Science ®Google Scholar
• Hayden C. GnRH analogues: applications in assisted reproductive techniques. Eur J Endocrinol 2008;159(Suppl 1):S17-25
   PubMed Web of Science ®Google Scholar
• Diedrich K, Diedrich C, Santos E, et al. Suppression of the endogenous luteinizing hormone surge by the gonadotrophin-releasing hormone antagonist Cetrorelix during ovarian stimulation. Hum Reprod 1994;9:788-91
   PubMed Web of Science ®Google Scholar
• Qublan HS, Amarin Z, Tahat YA, et al. Ovarian cyst formation following GnRH agonist administration in IVF cycles: incidence and impact. Hum Reprod 2006;21:640-4
   PubMed Web of Science ®Google Scholar
• Olivennes F, Diedrich K, Frydman R, et al. Safety and efficacy of a 3 mg dose of the GnRH antagonist cetrorelix in preventing premature LH surges: report of two large multicentre, multinational, phase IIIb clinical experiences. Reprod Biomed Online 2003;6:432-8
   PubMedGoogle Scholar
• Al-Inany HG, Abou-Setta AM, Aboulghar M. Gonadotrophin-releasing hormone antagonists for assisted conception: a Cochrane review. Reprod Biomed Online 2007;14:640-9
   PubMed Web of Science ®Google Scholar
• Olivennes F, Cunha-Filho JS, Fanchin R, et al. The use of GnRH antagonists in ovarian stimulation. Hum Reprod Update 2002;8:279-90
   PubMed Web of Science ®Google Scholar
• Broekmans FJ, Hompes PG, Lambalk CB, et al. Short term pituitary desensitization: effects of different doses of the gonadotrophin-releasing hormone agonist triptorelin. Hum Reprod 1996;11:55-60
   PubMed Web of Science ®Google Scholar
• Holland FJ, Fishman L, Costigan DC, et al. Pharmacokinetic characteristics of the gonadotropin-releasing hormone analog D-Ser(TBU)-6EA-10luteinizing hormone-releasing hormone (buserelin) after subcutaneous and intranasal administration in children with central precocious puberty. J Clin Endocrinol Metab 1986;63:1065-70
   PubMed Web of Science ®Google Scholar
• Reissmann T, Felberbaum R, Diedrich K, et al. Development and applications of luteinizing hormone-releasing hormone antagonists in the treatment of infertility: an overview. Hum Reprod 1995;10:1974-81
   PubMed Web of Science ®Google Scholar
• Devroey P, Aboulghar M, Garcia-Velasco J, et al. Improving the patient's experience of IVF/ICSI: a proposal for an ovarian stimulation protocol with GnRH antagonist co-treatment. Hum Reprod 2009;24:764-74
   PubMed Web of Science ®Google Scholar
• Bodri D, Guillen JJ, Galindo A, et al. Triggering with human chorionic gonadotropin or a gonadotropin-releasing hormone agonist in gonadotropin-releasing hormone antagonist-treated oocyte donor cycles: findings of a large retrospective cohort study. Fertil Steril 2009;91:365-71
   PubMed Web of Science ®Google Scholar
• Griesinger G, Diedrich K, Devroey P, Kolibianakis EM. GnRH agonist for triggering final oocyte maturation in the GnRH antagonist ovarian hyperstimulation protocol: a systematic review and meta-analysis. Hum Reprod Update 2006;12:159-68
   PubMed Web of Science ®Google Scholar
• Griesinger G, Diedrich K, Tarlatzis BC, Kolibianakis EM. GnRH-antagonists in ovarian stimulation for IVF in patients with poor response to gonadotrophins, polycystic ovary syndrome, and risk of ovarian hyperstimulation: a meta-analysis. Reprod Biomed Online 2006;13:628-38
   PubMed Web of Science ®Google Scholar
• Keay SD, Liversedge NH, Mathur RS, Jenkins JM. Assisted conception following poor ovarian response to gonadotrophin stimulation. Br J Obstet Gynaecol 1997;104:521-7
   PubMedGoogle Scholar
• Sunkara SK, Coomarasamy A, Khalaf Y, Braude P. A three-arm randomised controlled trial comparing Gonadotrophin Releasing Hormone (GnRH) agonist long regimen versus GnRH agonist short regimen versus GnRH antagonist regimen in women with a history of poor ovarian response undergoing in vitro fertilisation (IVF) treatment: Poor responders intervention trial (PRINT). Reprod Health 2007;4:12
   PubMedGoogle Scholar
• Lainas TG, Sfontouris IA, Zorzovilis IZ, et al. Management of severe OHSS using GnRH antagonist and blastocyst cryopreservation in PCOS patients treated with long protocol. Reprod Biomed Online 2009;18:15-20
   PubMed Web of Science ®Google Scholar
• Griesinger G, von Otte S, Schroer A, et al. Elective cryopreservation of all pronuclear oocytes after GnRH agonist triggering of final oocyte maturation in patients at risk of developing OHSS: a prospective, observational proof-of-concept study. Hum Reprod 2007;22:1348-52
   PubMed Web of Science ®Google Scholar
• Kosmas IP, Tatsioni A, Kolibianakis EM, et al. Effects and clinical significance of GnRH antagonist administration for IUI timing in FSH superovulated cycles: a meta-analysis. Fertil Steril 2008;90:367-72
   PubMed Web of Science ®Google Scholar
• Al-Inany H, Aboulghar M. Gonadotrophin-releasing hormone antagonists for assisted conception. Cochrane Database Syst Rev 2001;4:CD001750
   PubMedGoogle Scholar
• Ludwig M, Katalinic A, Diedrich K. Use of GnRH antagonists in ovarian stimulation for ART compared to the long protocol: a meta-analysis. Arch Gynecol Obstet 2001;265:175-82
   PubMedGoogle Scholar
• Kolibianakis EM, Collins J, Tarlatzis BC, et al. Among patients treated for IVF with gonadotrophins and GnRH analogues, is the probability of live birth dependent on the type of analogue used? A systematic review and meta-analysis. Hum Reprod Update 2006;12:651-71
   PubMed Web of Science ®Google Scholar
• Bokser L, Bajusz S, Groot K, Schally AV. Prolonged inhibition of luteinizing hormone and testosterone levels in male rats with the luteinizing hormone-releasing hormone antagonist SB-75. Proc Natl Acad Sci USA 1990;87:7100-4
   PubMed Web of Science ®Google Scholar
• Reissmann T, Schally AV, Bouchard P, et al. The LHRH antagonist cetrorelix: a review. Hum Reprod Update 2000;6:322-31
   PubMed Web of Science ®Google Scholar
• Cetrotide 0.25 mg Summary of Product Characteristics. Available from: http://emc.medicines.org.uk/medicine/8744/SPC/Cetrotide+0.25+mg/ [Accessed 28 May 2009]
   Google Scholar
• Cetrotide 3 mg Summary of Product Characteristics. Available from: http://emc.medicines.org.uk/medicine/8745/SPC/Cetrotide+3+mg/ [Accessed 28 May 2009]
   Google Scholar
• Cetrotide Package Insert. Cetrotide 0.25 mg and 3 mg (cetrorelix acetate for injection). USA: EMD Serono, Inc., 2004
   Google Scholar
• Fekete M, Bajusz S, Groot K, et al. Comparison of different agonists and antagonists of luteinizing hormone-releasing hormone for receptor-binding ability to rat pituitary and human breast cancer membranes. Endocrinology 1989;124:946-55
   PubMed Web of Science ®Google Scholar
• Sommer L, Zanger K, Dyong T, et al. Seven-day administration of the gonadotropin-releasing hormone antagonist Cetrorelix in normal cycling women. Eur J Endocrinol 1994;131:280-5
   PubMed Web of Science ®Google Scholar
• Pechstein B, Nagaraja NV, Hermann R, et al. Pharmacokinetic-pharmacodynamic modeling of testosterone and luteinizing hormone suppression by cetrorelix in healthy volunteers. J Clin Pharmacol 2000;40:266-74
   PubMed Web of Science ®Google Scholar
• Bokser L, Srkalovic G, Szepeshazi K, Schally AV. Recovery of pituitary-gonadal function in male and female rats after prolonged administration of a potent antagonist of luteinizing hormone-releasing hormone (SB-75). Neuroendocrinology 1991;54:136-45
   PubMed Web of Science ®Google Scholar
• Ayalon D, Farhi Y, Comaru-Schally AM, et al. Inhibitory effect of a highly potent antagonist of LH releasing hormone (SB-75) on the pituitary gonadal axis in the intact and castrated rat. Neuroendocrinology 1993;58:153-9
   PubMed Web of Science ®Google Scholar
• Engel J, Rieger L, Dietl J, Honig A. The GnRH antagonist cetrorelix: established indications and future potential. Exp Rev Obstet Gynecol 2007;2:431-40
   Google Scholar
• Albano C, Smitz J, Camus M, et al. Comparison of different doses of gonadotropin-releasing hormone antagonist Cetrorelix during controlled ovarian hyperstimulation. Fertil Steril 1997;67:917-22
   PubMed Web of Science ®Google Scholar
• Olivennes F, Alvarez S, Bouchard P, et al. The use of a GnRH antagonist (Cetrorelix) in a single dose protocol in IVF-embryo transfer: a dose finding study of 3 versus 2 mg. Hum Reprod 1998;13:2411-4
   PubMed Web of Science ®Google Scholar
• Felberbaum R, Reissmann T, Kupker W, et al. Hormone profiles under ovarian stimulation with human menopausal gonadotropin (hMG) and concomitant administration of the gonadotropin releasing hormone (GnRH)-antagonist Cetrorelix at different dosages. J Assist Reprod Genet 1996;13:216-22
   PubMed Web of Science ®Google Scholar
• Albano C, Felberbaum RE, Smitz J, et al. Ovarian stimulation with HMG: results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin. European Cetrorelix Study Group. Hum Reprod 2000;15:526-31
   PubMed Web of Science ®Google Scholar
• Olivennes F, Belaisch-Allart J, Emperaire JC, et al. Prospective, randomized, controlled study of in vitro fertilization-embryo transfer with a single dose of a luteinizing hormone-releasing hormone (LH-RH) antagonist (cetrorelix) or a depot formula of an LH-RH agonist (triptorelin). Fertil Steril 2000;73:314-20
   PubMed Web of Science ®Google Scholar
• Felberbaum RE, Albano C, Ludwig M, et al. Ovarian stimulation for assisted reproduction with HMG and concomitant midcycle administration of the GnRH antagonist cetrorelix according to the multiple dose protocol: a prospective uncontrolled phase III study. Hum Reprod 2000;15:1015-20
   PubMed Web of Science ®Google Scholar
• Hsieh YY, Chang CC, Tsai HD. Comparisons of different dosages of gonadotropin-releasing hormone (GnRH) antagonist, short-acting form and single, half-dose, long-acting form of GnRH agonist during controlled ovarian hyperstimulation and in vitro fertilization. Taiwan J Obstet Gynecol 2008;47:66-74
   PubMed Web of Science ®Google Scholar
• Xavier P, Gamboa C, Calejo L, et al. A randomised study of GnRH antagonist (cetrorelix) versus agonist (busereline) for controlled ovarian stimulation: effect on safety and efficacy. Eur J Obstet Gynecol Reprod Biol 2005;120:185-9
   PubMed Web of Science ®Google Scholar
• Huirne JA, Hugues JN, Pirard C, et al. Cetrorelix in an oral contraceptive-pretreated stimulation cycle compared with buserelin in IVF/ICSI patients treated with r-hFSH: a randomized, multicentre, phase IIIb study. Hum Reprod 2006;21:1408-15
   PubMed Web of Science ®Google Scholar
• Wikland M, Bergh C, Borg K, et al. A prospective, randomized comparison of two starting doses of recombinant FSH in combination with cetrorelix in women undergoing ovarian stimulation for IVF/ICSI. Hum Reprod 2001;16:1676-81
   PubMed Web of Science ®Google Scholar
• Wilcox J, Potter D, Moore M, et al. Prospective, randomized trial comparing cetrorelix acetate and ganirelix acetate in a programmed, flexible protocol for premature luteinizing hormone surge prevention in assisted reproductive technologies. Fertil Steril 2005;84:108-17
   PubMed Web of Science ®Google Scholar
• Rongieres-Bertrand C, Olivennes F, Righini C, et al. Revival of the natural cycles in in-vitro fertilization with the use of a new gonadotrophin-releasing hormone antagonist (Cetrorelix): a pilot study with minimal stimulation. Hum Reprod 1999;14:683-8
   PubMed Web of Science ®Google Scholar
• Pelinck MJ, Vogel NE, Hoek A, et al. Minimal stimulation IVF with late follicular phase administration of the GnRH antagonist cetrorelix and concomitant substitution with recombinant FSH: a pilot study. Hum Reprod 2005;20:642-8
   PubMed Web of Science ®Google Scholar
• Pelinck MJ, Vogel NE, Arts EG, et al. Cumulative pregnancy rates after a maximum of nine cycles of modified natural cycle IVF and analysis of patient drop-out: a cohort study. Hum Reprod 2007;22:2463-70
   PubMed Web of Science ®Google Scholar
• Akman MA, Erden HF, Tosun SB, et al. Comparison of agonistic flare-up-protocol and antagonistic multiple dose protocol in ovarian stimulation of poor responders: results of a prospective randomized trial. Hum Reprod 2001;16:868-70
   PubMed Web of Science ®Google Scholar
• Cheung LP, Lam PM, Lok IH, et al. GnRH antagonist versus long GnRH agonist protocol in poor responders undergoing IVF: a randomized controlled trial. Hum Reprod 2005;20:616-21
   PubMed Web of Science ®Google Scholar
• De Placido G, Mollo A, Clarizia R, et al. Gonadotropin-releasing hormone (GnRH) antagonist plus recombinant luteinizing hormone vs. a standard GnRH agonist short protocol in patients at risk for poor ovarian response. Fertil Steril 2006;85:247-50
   PubMed Web of Science ®Google Scholar
• Martínez F, Coroleu B, Marqués L, et al. Comparison of “Short Protocol” versus “Antagonists” with or without Clomiphene Citrate for stimulation in IVF of patients with “low response”. Revista Iberoamericana de Fertilidad (in Spanish with English abstract) 2003;20:355-60
   Google Scholar
• Hwang JL, Seow KM, Lin YH, et al. Ovarian stimulation by concomitant administration of cetrorelix acetate and HMG following Diane-35 pre-treatment for patients with polycystic ovary syndrome: a prospective randomized study. Hum Reprod 2004;19:1993-2000
   PubMed Web of Science ®Google Scholar
• Bahceci M, Ulug U, Ben-Shlomo I, et al. Use of a GnRH antagonist in controlled ovarian hyperstimulation for assisted conception in women with polycystic ovary disease: a randomized, prospective, pilot study. J Reprod Med 2005;50:84-90
   PubMed Web of Science ®Google Scholar
• Kim C-H, Lee Y-J, Hong S-H, et al. Efficacy of a GnRH antagonist during early and late controlled ovarian hyperstimulation period in women with polycystic ovary syndrome undergoing IVF-ET. Hum Reprod 2004;19(Suppl 1):i104-5
   PubMed Web of Science ®Google Scholar
• Ashrafi M, Mohammadzadeh A, Ezabadi Z, Baghestani AR. A comparative study of GnRH-ant and GnRH-ag protocols in IVF-ICSI in PCOD patients. Iranian J Reprod Med 2005;3:14-18
   Google Scholar
• Ragni G, Vegetti W, Riccaboni A, et al. Comparison of GnRH agonists and antagonists in assisted reproduction cycles of patients at high risk of ovarian hyperstimulation syndrome. Hum Reprod 2005;20:2421-5
   PubMed Web of Science ®Google Scholar
• Papanikolaou EG, Pozzobon C, Kolibianakis EM, et al. Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles. Fertil Steril 2006;85:112-20
   PubMed Web of Science ®Google Scholar
• Ludwig M, Katalinic A, Felberbaum RE, Diedrich K. Safety aspects of gonadotrophin-releasing hormone antagonists in ovarian stimulation procedures: ovarian hyperstimulation syndrome and health of children born. Reprod Biomed Online 2002;5(Suppl 1):61-7
   PubMedGoogle Scholar
• Fauser BC, Devroey P. Why is the clinical acceptance of gonadotropin-releasing hormone antagonist cotreatment during ovarian hyperstimulation for in vitro fertilization so slow? Fertil Steril 2005;83:1607-11
   PubMed Web of Science ®Google Scholar
• Al-Inany H, Aboulghar M. GnRH antagonists in assisted conception: a Cochrane Review. Hum Reprod 2002;17:874-85
   PubMed Web of Science ®Google Scholar
• Griesinger G, Felberbaum R, Diedrich K. GnRH antagonists in ovarian stimulation: a treatment regimen of clinicians' second choice? Data from the German national IVF registry. Hum Reprod 2005;20:2373-5
   PubMed Web of Science ®Google Scholar
• Rackow BW, Kliman HJ, Taylor HS. GnRH antagonists may affect endometrial receptivity. Fertil Steril 2008;89:1234-9
   PubMed Web of Science ®Google Scholar
• Bahceci M, Ulug U, Sismanoglu A, et al. Early pregnancy loss rates were different among singleton gestations conceived by ICSI using GnRH agonist and antagonist. J Assist Reprod Genet 2009;26:227-9
   PubMed Web of Science ®Google Scholar
• Prapas N, Prapas Y, Panagiotidis Y, et al. GnRH agonist versus GnRH antagonist in oocyte donation cycles: a prospective randomized study. Hum Reprod 2005;20:1516-20
   PubMed Web of Science ®Google Scholar
• Vlahos NF, Bankowski BJ, Zacur HA, et al. An oocyte donation protocol using the GnRH antagonist ganirelix acetate, does not compromise embryo quality and is associated with high pregnancy rates. Arch Gynecol Obstet 2005;272:1-6
   PubMedGoogle Scholar
• Saucedo de la Llata E, Moraga Sanchez MR, Batiza RV, et al. Comparison of GnRH agonists and antagonists in an ovular donation program. Ginecol Obstet Mex (in Spanish with English abstract) 2004;72:53-6
   PubMedGoogle Scholar
• Prapas N, Tavaniotou A, Panagiotidis Y, et al. GnRH antagonists and endometrial receptivity in oocyte recipients: a prospective randomized trial. Reprod Biomed Online 2009;18:276-81
   PubMed Web of Science ®Google Scholar
• Bukulmez O, Carr BR, Doody KM, Doody KJ. Serum cetrorelix concentrations do not affect clinical pregnancy outcome in assisted reproduction. Fertil Steril 2008;89:74-83
   PubMed Web of Science ®Google Scholar
• Bahceci M, Ulug U, Erden HF, et al. Frozen-thawed cleavage-stage embryo transfer cycles after previous GnRH agonist or antagonist stimulation. Reprod Biomed Online 2009;18:67-72
   PubMed Web of Science ®Google Scholar
• Lin YH, Seow KM, Chen HJ, et al. Impact of estradiol patterns in clomiphene citrate/human menopausal gonadotropin/cetrorelix protocol. Gynecol Endocrinol 2007;23:45-9
   PubMed Web of Science ®Google Scholar
• Al-Inany H, Aboulghar MA, Mansour RT, Serour GI. Optimizing GnRH antagonist administration: meta-analysis of fixed versus flexible protocol. Reprod Biomed Online 2005;10:567-70
   PubMed Web of Science ®Google Scholar
• Tur-Kaspa I, Cohen A, Tkachenko N, et al. GnRH antagonist (Cetrotide) instead of agonist to prepare recipients for embryo transfer: a prospective, randomized, controlled trial. Fertil Steril 2008;90:S382
   Google Scholar